#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypoxic-ischaemic encephalopathy Scedosporium infection Rheumatoid arthritis Skin angiosarcoma Cutaneous calcification Ventricular tachycardia Short stature homeobox gene mutation Alexander disease Gastric cancer Crigler-Najjar syndrome Enteritis Neuroblastoma Facioscapulohumeral muscular dystrophy Osteosarcoma metastatic Leiomyosarcoma More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia Factor VIII deficiency – Trials in Disease Langerhans cell sarcoma – Treatment Glomerulonephritis rapidly progressive – Trials in Disease Leiomyosarcoma metastatic – Diagnostics Soft tissue sarcoma – Basic Information Stevens-Johnson syndrome – Basic Information Angiosarcoma metastatic – Life with Disease Myelodysplastic syndrome – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Botensilimab Phosphocreatine Sodium Mannitol Lithium Sulphate, Anhydrous Trametinib Vx-670 IPN01195 Temozolomide Tiotropium Bromide Fexofenadine GSK5733584 Guselkumab Corline Heparin Conjugate BENZYDAMINE HYDROCHLORIDE Tng462 Fluticasone Octocog Alfa Mirvetuximab Soravtansine Ale.c04 Rasagiline More therapies…

    Learn about Your Condition

    Toxic epidermal necrolysis Aortic disorder Herpes zoster Epileptic encephalopathy Tooth loss Metastases to lymph nodes Pleomorphic leiomyosarcoma Arginase deficiency Non-Hodgkin's lymphoma Caesarean section Plasma cell myeloma recurrent Salivary gland cancer Neuropathy peripheral Hypercholesterolaemia Cholangitis sclerosing More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Immune System Diseases

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Tocilizumab
    Germany Italy Poland Spain

  • Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Benralizumab
    France The Netherlands Poland

  • A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Chronic cutaneous lupus erythematosus
    • Cutaneous lupus erythematosus
    • Subacute cutaneous lupus erythematosus
    Belgium Bulgaria Czechia France Germany Greece +4
1 2 3 … 131
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!